General Assembly



Minutes of the general assembly of July 2nd 2012

All the members of the ARMGHM association have met at the « Maison de la Gibauderie » on July 2nd 2012.
The agenda was:
- moral and activity report from the President,
- financial report,
- approval of the accounts,
- appropriation of the result.

Besides, an extraordinary general meeting also took place to proceed to the amendments to the Articles given the ongoing projects.

The President presents the activity of the association in respect of the 2011 Financial Year as well as the difficulties and current projects.
He provides the moral and activity report of the association.
He presents the annual financial statements being a loss of € 26.670,49.

After discussion, he moved on to the vote of the following resolutions:

First resolution
The general Assembly, approved at voters’ unanimity, the moral and activity report of the association as well as the financial statement for the year ending 31.12.2011 and operations relating to this exercise.
The association discharge the President and the members of the management board in respect of the previous financial year.
The association decides to carry forward the losses of € 26.670,49.

Second resolution (extraordinary general assembly)
The members of the association decide the revision of the statutes and finalise their text according to the project attached as an appendix.

Third resolution
The general assembly proceeds to elect its management board.
Are designated by the Scientific Council:
Mr Hossein MOSSAFA
Geneticist,

Are designated by the founding members:
Monsieur Franck VIGUIE,
lecturer-researcher and medical geneticist,
Monsieur Philippe DESSEN,
bio-informatician,

In addition, are elected by the assembly:
Monsieur Jean-Loup HURET
lecturer-researcher and medical geneticist,
Monsieur Jean-Marie NICOLAS,
Chamber vice president at the commercial court of Evry
Monsieur Alain BERHEIM,
researcher and medical geneticist,
Monsieur Philippe MISSEREY,
lawyer,
Monsieur Bernard DROCHON,
public accountant,
Madame Marie-Christine BOLINCHES,
general delegate of an occupational trade union,
Monsieur François DESANGLES,
geneticist,
Madame Martine JAMMET,
company manager,

Fourth resolution
Full powers are granted to the President to ensure the disclosure formalities stipulated by legislation.

The President - Jean Loup HURET
An administrator - Martine JAMMET



Minutes from the General Assembly of the ARMGHM Association – Cancer Genetics of the 27/05/2013

Members present at the Annual General Meeting:
Jean Loup Huret, President, Bernard Drochon, Treasurer, Martine Jammet, Secretary, Dominique Penther, Representing the French speaking Group of Hematologic Cytogenetic, Anthony Brouard, Accountant of the association, Jacques Wintrebert, Retired, Jean-Louis Duchet, Honorary Dean , Marc Mesnil, Professor, Joelle Roche, Professor, Franck Viguié, Cytogeneticist, Sébastien Guilbault, Jeune Chambre Economique / Young Economic Chamber.
Notably Absent : Hossein Mossafa, Vice-President, Lucienne Michaux, Representing the Belgian Society of Human Genetics, Philippe Dessen, Director of the database, and numerous members of the association, especially those living overseas, but having given their proxy. 

2012 Moral and activities Report from the Atlas of Cancer Genetics’ association - ARMGHM
I- Drafting of the new statute of the association, presented July 2nd 2012 at the general assembly. Henceforth, the association’s name is "Atlas of Cancer Genetics- ARMGHM", instead of "Association for the Research on Genetic Diseases and Mental Disability".
The 2nd article of the statute, defining the object of the association, stipulate: « The purpose of the association is to promote information on genetic anomalies acquired in the cancer field by developing the Atlas and any scientific or research activity related to the field. The association is notably in charge of carrying out the management, updating, edition, publication and distribution of the online encyclopaedia referred to as “ Atlas of Genetics and Cytogenetics in Oncology and Haematology “as well as its content and by all means. Accessing this internet database is public and free of charge.
The management board is composed of:
Alain Bernheim,
Marie-Christine Bolinches,
François Desangles,
Philippe Dessen,
Bernard Drochon, Treasurer,
Jean Loup Huret, President,
Martine Jammet, Secretary,
Lucienne Michaux, representing the Belgian Society of Human Genetics (BeSHG), and President of the Belgian Cytogenetics Group in Haematology and Oncology (BCGHO),
Philippe Misserey,
Hossein Mossafa, Vice-President,
Jean-Marie Nicolas,
Dominique Penther, Representing the French speaking Cytogeneticist Association (ACLF), and member of the board of the French speaking Group of Hematologic Cytogenetic (GFCH),
Franck Viguié.

II- A three-year agreement on objectives and resources has been signed in March 2012 between the Association, the University of Poitiers and Poitiers’ University Hospital. 

III- Signing a three-year patronage agreement with CERBA laboratory.

IV- Continuation of the collaboration with the “CRITT informatics” for the setting-up of a new database which will replace the current website.
V- The Atlas’ Progress:
The cards created by Poitiers’ group are released on-line (generally on a weekly basis).
229 cards over 2012 (145 Genes, 43 Leukaemia, 21 solid Tumours, 8 Cancer Prone Diseases, 7 Deep Insight and 5 Clinical Case Reports)
The list of potentially implicated genes is weekly updated (based on the annotations from Entrez on NCBI (more than 8400 non annotated genes on top of the 1200 annotated genes).
Update of the database concerning the annotation of these genes and allowing the creation of the external hyperlinks.
Moreover, several improvements on the standardisation and nomenclatures have been made to the cards: Classification tree of tumours’ name, assignment to translocations or genes fusions.
Besides the tremendous work on the validation of the cards’ identifiers (Atlas ID), a work on the interlinking of the anomalies with Mitelman website led to the definition of common thesaurus between the Atlas and the Mitelman database, this allows a better interconnection between the two highly complementary databases. We started to generate several tables with hyperlinks allowing visualising the different aberrations and the associated genes by chromosomal bands (This task should be completed within few weeks).

As part of the evolutions from the cytogenetic to the cytogenomic domain, going towards the descriptions of the aberrations at the DNA sequence level with new technologies, a reflexion on the necessity to comprehend this more precise new information is essential. We need to follow-up the literature and the databases in order to report the maximum of chromosome rearrangements or gene fusion at the DNA sequence level.

Search for new partnership with other European groups in order to develop new European projects. Discussions are engaged on human proteomic database and the role and expertise that the Atlas could provide in cytogenetic anomalies in cancer.
Finally, a follow-up on the progression of the new database developed by the CRITT must lead to integrate new tools facilitating its management and its ongoing evolution. This has to be conducted in conjunction with a regional decision to put the database online on Poitiers’ University website.
Electronic Journal of the Atlas: collaboration with the INIST from the CNRS for the online publication of the archives of a quarterly journal published at an international level which started in1997, then went from 4 to 6 issues in 2008, and reached 12 issues in 2009. At the end of 2012, the Electronic Journal was comprised of 2 307 articles in 101 issues, and 8 264 ‘peer reviewed’ articles pages. 209 articles in 12 issues (representing 1095 pages) were added in 2012 (http://documents.irevues.inist.fr/handle/2042/15655). We filled an application to be referenced on PubMed, the American database referencing the world biomedical literature.

Financial Report (abstracts)
I- outturn account
The operating revenues (€ 183 201) are mostly composed of subsidies (136 818 €)
- Grant from FEDER (€ 101 818)
(Representing 55 % against 72 % upon 2011)
- Social subsidies (€ 5 394)
- Divers Grants (€ 56 615)
And other products (€ 19 383)

The Operating expenses amount to € 177 701, which is 14 % less than in 2011, they are constituted at 81 % by staff cost (€ 144 415) and at 8 % by CRITT informatics services and support (€ 13 900).

There were no significant variations of any other items of expenditure.
Under these conditions, the net income for 2012, after financial result (+ € 737) and extraordinary result (+ € 766) is a gain of 7004 Euros.

II- Comments
The forecast of the ARMGHM association activity is established for a four-year duration (from 2013 to 2016 included).
It is related to the operating items as part of the accounting of the commitment from the 2011 annual accounts and the 2012 achievements (before the end of the fiscal year for the final order).
The operating revenue are estimated according to what has already been achieved, intentions that have been expressed to the association and negotiations under way.
The budgeted cost is carefully estimated according to the structure directed by the purpose of the association but also according to constraints linked to it, in particular with regard to the staff costs.
The item of expenditure "other charges" includes uncertainties linked to events external to the association, mainly general cyclical effects or specific to the nature of its activity.

Into those conditions the summary operating accounts are self-balancing but subject to:
- the releasing of the estimated resources
- the good management of the estimated expenses
- and the realisation of the expected revenues and estimated in "other products". They constitute in fact, to say the least, the real needs of the association.

Each views expressed have been recorded hereto and no objections were made.

The items on the agenda having been covered, the meeting was declared closed.



Official record of the ARMGHM general meeting, May 2014- Atlas of genetics in cancer

Maison de La Gibauderie
Poitiers, 12 May 2014
Present: François Desangles, Philippe Dessen, Bernard Drochon, Jean Loup Huret, Martine Jammet, Philippe Misserey, Hossain Mossafa, Jean-Marie Nicolas, Jacques Wintrebert.

Annual moral and activity report
Jean Loup Huret, president of the association presented a synthesis of the moral and activity report of the Atlas Génétique des Cancers - ARMGHM association, providing details on the financial difficulties we encountered in October 2013 and on our successful appeal to the Fondation Neila et Amadeo Barletta (FNAB), through which we quickly obtained 30 000€ and then 60 000€ for January-June 2014, and were promised the same amount of money for July-December 2014 in return for a structured project. 
He then explained that the president of the foundation wished to see the Atlas reorganized and placed under the trusteeship of the IUH (Institut Universitaire d’Hématologie of l'Hôpital Saint Louis in the EA3518 reception team).  Jean Loup Huret added that unlike the Paris-Diderot university, the IUH is not a legal entity, and he mentioned that in addition to or in the place of  the IUH, a new foundation is being set up.  To conclude, Jean Loup Huret asked us to think over what was being proposed. The initial FNAB project FNAB would be a devolution of the association in favor of the IUH, but during the most recent association-IUH-FNAB meeting, the IUH appeared to appreciate an advantage of the associative system: the fact that the IUH would not be legally compelled to offer long-term (CDI) contracts to staff, following the maximally 6-year short-term (CDD) contracts provided for in the Sauvaget law. At the very least, keeping staff within the association "buys time" for the IUH.

Financial report
Bernard Drochon, treasurer of the association, provided comments on the financial report, indicating that the results for the financial year 2013 showed a deficit of 30245€, while the net financial situation of the association came to +55 932€ He added that for 2014 no grant from any source other than the FNAB was anticipated, and that, more specifically, we would no longer benefit from the financial support of the DRIRE (FEDER European funds). Bernard Drochon also mentioned that during the previous year, we had asked the Fédération des Banques for support, which was refused due to the difficulty of raising funds. Bernard Drochon concluded that were devolution not to occur, he would resign as treasurer.  He would like to receive mail from the IUH indicating their intention to finance the association (amount of money, number of years).
Hossain Mossafa raised the issue of the association's 5 salaried employees.  Bernard Drochon and Hossain Mossafa insisted that it was out of the question to leave things as they were, given the fact that in 2013, financial problems greatly hindered and hampered the efforts of Jean-Loup Huret.

Who is to take charge of the devolution project?
Bernard Drochon explained that it was not normal for us to be the only ones to carry out the devolution project and said it was necessary for is to engage discussions with a jurist representing the IUH. Philippe Dessen and Jean Loup Huret pointed out that we would not have as an outside interlocutor a lawyer, ready to dialogue with our lawyer, but rather an anonymous provider of legal services, who would reject or accept our proposed project.  

What are the key constituents of exchanges between our association and the IUH?
According to Philippe Misserey, four highly important constituents need to be taken into account:
- The salaried employees
- The management of electronic information tools (hosting)
-The affiliation of the group (Atlas) (note: If the CHU is not interested, management will be simpler)
- The geographical site
Once these 4 key points have been clearly determined, it will be easier to defined the right type of governance.

What solution(s)?
Jean-Marie Nicolas stated that as we no longer had the means to proceed as previously, there were only two possible solutions: 1-the solution that we desire and that we should try to impose: the transfer of all the salaried employees to the IUH; if not, 2 -in the event that we were compelled to continue to have employees under contract, we should demand, in exchange, written assurance from the FNAB of their financing over a period of X years.   
Hossain Mossafa pointed out that in any case, we shall require a validated 5-year project, which would evidently be parallel to a structured scientific project.
If the association has to retain its salaried employees, it is possible to imagine allocating sums of money sufficing to cover possible severance payments (27681€ on 31/12/13).
Philippe Dessen affirmed that a hybrid solution - some employees in Paris, others in Poitiers and, more particularly, two distinct employers, the IUH and the association - would be unsatisfactory.  
Philippe Misserey expressed concern over the fact that were the solution mandating the IUH to finance salaries were to be adopted, at a time when the IUH would not have - or wish to have - a budget permitting these salaries to be paid, it would be necessary to explore the means of recourse of which our association could avail itself.
Hossain Mossafa pointed out that we should be partially reassured by the fact that just like large pharmaceutical corporations, the IUH is keenly interested in the works of the Atlas.  

Should members of the foundation and of the IUH be members of the Bureau of the association?
The president of the FNAB foundation has awarded us money without asking for anything in return; Bernard Drochon does not consider this normal. Hossain Mossafa pointed out that a foundation's role consists not in managing, but rather in monitoring the funds it has awarded; in any case, that is the model to be found in our research structures. François Desangles proposed active participation of the IUH in Atlas governance, while Bernard Drochon suggested that members of the foundation and the IUH should be members of the Bureau of the association. Jacques Wintrebert expressed agreement with this recommendation, affirming that it would induce our interlocutors to get more closely involved in the activities of our association; all participants at the general meeting were of the same opinion.   
Once a given number of years shall have elapsed, it might be possible to envision devolution to the IUH, the terms of which would be defined in a convention.

Devolution of the association in favor of the IUH, or convention?
Philippe Misserey said that devolution was a figment of the imagination, and asserted that it would be more reasonable to draw up a convention by elaborating a contract of objectives.  
The participants agreed that as a first step, a convention would be the best solution for the association.  
A meeting with the FNAB and the IUH, to be held by the end of the week, was recommended.

It was consequently put to the vote of the general assembly  that, on the occasion of the meeting with the FNAB and the IUH:
Confirmation be given to the FNAB and the IUH that: 1- We are ready for devolution to the IUH; 2- Were the IUH to deem this devolution to be premature, we would commit ourselves to remunerated activity in the association, on the strict condition of a written financial commitment from the FNAB with regard to salaries over the periods of employment of possible short-term (CDD) employees, and for a period of 2 years of salaries + severance pay and month of notice for long-term (CDI) employees. In the second case, conventions would be signed with the IUH and the FNAB.  It would also be requested that a representative of the FNAB and a representative of the IUH sit on the board of directors (conseil d'administration) of the association.

Vote on a resolution
After having heard the report by Jean-Loup Huret entitled "projet ATLAS-IUH",  the participants at the general meeting approved both the contents and the proposed strategy.

The general assembly consequently authorized the president to implement all solutions and operations envisioned in the framework of this project and, more generally, do proceed as necessary in view of prolonging the activities of the Atlas in partnership with the Institut Universitaire d’Hématologie.

The resolution was unanimously approved.
Vote on the resolution: 48 votes for (the 9 members present and the 39 members "good for proxy"); 0 votes against, 0 abstentions, out of fee-paying 61 members.



Report devolution 01-2015

The association 'ARMGHM Atlas de Génétique des Cancers' was founded in 1993. It is a not-for-profit organization under French law (law 1901), whose purpose is to host and handle the Atlas of Genetics and Cytogenetics in Oncology and Haematology, to facilitate its editorial process and to ensure the propagation of its contents.

The Atlas is a peer-reviewed journal / encyclopaedia / internet database aimed at genes involved in cancer, cytogenetics and leukemias, solid tumours, and cancer-prone diseases. It also comprises educational items in genetics for students.
It presents structured reviews (cards) or traditional review papers (Deep insights), a portal towards genetics and/or cancer databases and journals, teaching items in Genetics for students in Medicine and in Sciences, and a Case report section. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. Contributions are reviewed before acceptance. It deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using new information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It is in free access on the Internet.

However, its management requires financial resources that are more and more difficult to obtain.
The Association has four employees (Mohammad AHMAD, Mélanie ARSABAN, Vanessa LEBERRE, Anne MALO).
Accounts were hardly balanced in 2012, and showed a deficit of 30.000 € for 2013.

The bureau of the executive board was therefore in search for a sustainable and perennial source of funding.
Various actors (local authorities and public international bodies such as Europe, the University and University Hospital of Poitiers, charities, scientific societies) tried to find appropriate solutions, but could not ensure the long-term at a sufficient level.
The only perennial solution was to join and build on a University structure. This is how we met with the
University Institute of Hematology (IUH) Saint-Louis-Paris VII.
Members of the IUH decided to create a new association, called: association 'Atlas de Génétique des Cancers', hosted within the IUH, bâtiment George Hayem, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France. This new association is directed by Raouf BEN ABDELALI, Associate Professor, Professor Catherine THIEBLEMONT is treasurer of the association, and Professor Hervé DOMBRET (who is also Director of the IUH) is secretary of the association.
The goal of future association 'Atlas de Génétique des Cancers'is to pursue the mission and goals of our association 'ARMGHM - Atlas de Génétique des Cancers'.

We herein propose that the association 'ARMGHM - Atlas de Génétique des Cancers' is dissolved, that all debts are paid, and that a devolution of the Atlas to the new association 'Atlas de Génétique des Cancers'occurs.
In accordance with Article 9 of the law of July 1, 1901, the devolution will give effect to the transfer to the new association so that the Atlas will continue to be available to the medical and/or scientific community, given that our association will lapse.

The devolution of the Atlas consists in a number of entities:

1- Atlas developments, since it has been created, consist in articles (individual cards, classified into various categories (Genes, Leukemias, Solid Tumors, Cancer-Prones Diseases, Case Reports, Deep Insights, Educational Items), the content of which remains the property of the authors, and the structure of this content the editorial process.
This content, on-line at the INIST server, is part of the devolution (a transmission of archives files at the date 12/31/014 may be done).
2-The structuration, articulation, and navigation between the data is made of a series of scripts and computer programs, including scripts and computer programs for updating at an individual and / or at the global level. A collection of these scripts and computer programs may be included in the devolution. However, new scripts and computer programs will replace them in a new/future database, programmed for being effective before July 2015.
3- Archives of the editorial group (mails with authors, addresses of authors, list of subjects to be addressed …) are part of the devolution.
4- The staff devoted to this editorial work.
5- The name "Atlas of Genetics and Cytogenetics in Oncology and Haematology", as well as domain names registered by our association : "atlasgeneticoncology.org", "chromosomesincancer.org". Even in the case these domain names would not be used anymore, it is essential that they are maintained in the property of the Atlas, to avoid that they are misused.
6- The Atlas is hosted by the INIST (Institute for scientific and technical information of the CNRS, French National Center for Scientific Research), although there is no current web hosting agreement. The continuity of web hosting will need renegotiation with INIST. Meanwhile, to ensure continuity of service, the current website will continue to be administered by the former senior team.
7- The equipment (computers, office chairs ...).
8- The cash.

The advantage of the project for our association is to be liable for all legal and financial commitments towards the Atlas.
The disadvantage is the lack of clarity concerning the project; the new structure will be enabled to what they want, without constraints or commitment to us.
But we have tried and exhausted seeking alternative solutions and we cannot continue 2015 under the same conditions as 2014.

I, Jean-Loup HURET, President of the association, propose you to vote in favor of this project.
Done in Poitiers,
December, the 31st, 2014br />

Jean Loup HURET



Official record of the 30 June 2015 general meeting of the ARMGHM - Atlas of Genetics in cancer

Present or represented (having given a proxy) at the general meeting:  
Jean Loup Huret, President, Hossein Mossafa, Vice-President, Bernard Drochon, Treasurer, Martine Jammet, Secretary, Philippe Dessen, Database Director, Adriana Zamecnikova, Aurelia Meloni-Ehrig, Baptiste Gaillard, Brenda Lauffart, Charles Bangs, Chrystèle Bilhou Nabera, Claus Kerkhoff, Dan Van Dyke, Diane Jordan, Holly H Hobart, Jacques Wintrebert, Jean-Marie Nicolas, Jean-Michel Dupont, Jing Liu, Julia Bridge, Julie Sanford Biggerstaff, Katrina Vanura, Marc De Braekeleer, Nathalie Nadal, Nyla Heerema, Orjan Petersson, Oskar Haas, Paola Silvia Dal Cin, Roberta Vanni, Roberto Rosati, Susana Raimondi,
, in total 31 persons.
Number of members: 50. The quorum has been reached.

I- 2014 moral and activity report
On 27 January 2015: First there was first a board of directors meeting, and then an extraordinary general meeting in which it was decided to conclude the devolution of the Atlas to a new association, inspired by the Institut Universitaire d'Hématologie (IUH) Paris VII- Hôpital Saint Louis, in view of gradually transferring the Atlas and its management to a new structure with new actors and a new data base. However, the FNAB foundation, which had been financing our activities, brutally withdrew its support, the decision being made arbitrarily, apparently without any prior meeting of its scientific committee. Not a single FNAB director formalized the decision in writing. The FNAB had previously forced our association to hire on a temporary basis a new collaborator working under the authority of the FNAB itself (unusual interference in the universe of scientific grants!). In fact, it was through the intermediation of this double-hatted collaborator that we were notified of the FNAB decision to suddenly withdraw the totality of its support! As for the IUH, which had no specific financial means dedicated to the Atlas, it had no choice but to pull out. And on 13 March 2015, we in turn had no choice but to lay off all employees of the association for economic reasons. The editorial staff of the Atlas was consequently totally dismantled. 
We have nonetheless carried on with the development of bio-informatic tools characterizing the Atlas, which has been kept online by the INIST (CNRS, Nancy). Several rounds of discussion have been devoted to renovation of the Atlas's IT structure. Numerous reactions to alarm signals concerning its possible disappearance (see: http://atlasgeneticsoncology.org/Supporting_Atlas_First_signatories.pdf) have induced a group of American cytogeneticists to put forward a number of proposals to either take over or closely associate themselves with the Atlas. Collaboration with an Italian group and continuation with the Amos Bairoch group are currently taking form. The creation of "mirror" or associated sites deserves further study, and discussions with a scientific press group have been undertaken.  

Recent developments
Nosology, thesaurus and inventorying: Major work associating the ICD-03 (International Classification of Disease-Oncology) descriptors with various articles in the Atlas has been carried out. See http://atlasgeneticsoncology.org/Tumors/Solid_Nosology.html .
Resource integration: Online publication of work concerning: a) the integration of numerous resources on gene abnormalities and fusions originating in the international tumor programs (Mitelmnan,  Cosmic, TicDB, ChiTars, TCGA and ICGC) and b) compilations from the published literature on tumor cell lines, with the development of a chromosomal band interface (440). Example: http://atlasgeneticsoncology.org/Bands/1p36.html.
Extension to 27000 genes: Extension of the list of accessible genes with "linked" information on an exceedingly wide variety of Internet sites.  The Atlas presently contains close to 27000 genes (list limited to the genes located in the human genome) http://atlasgeneticsoncology.org/Genes/Geneliste.html .
Scripts: Improvement of the management scripts enabling generation of an Atlas on any computer equipment under UNIX or a similar operating system (Cygwin on Windows or MacOS) for use of locally usable versions (without Internet). This will allow the different persons potentially associated in a consortium to carry out an overhaul and proceed to further IT development.   
Authors: To date, 3117 authors have written one or more articles for the Atlas.  

II- Financial report
General financial statement
Following amortization, fixed assets are valued at 16€.
No movement was observed during the 2014 fiscal year. Assets valued before amortization at 80596€ consist mainly in a website valued at 72076€.
Current assets come to 78816€, including  77576€ of liquid assets on 31 December 2014.  
Liabilities consist in normal and current debts and in provisions for accruals. The association has incurred no bank indebtedness.
Under these conditions and taking into account a deficit result amounting to 4373€, the net position of the association comes to 51558€.
Profit and loss account
Operating revenue (142,019€) is mainly represented by:
-grants            132,969€
-donations and membership fees      2050€
-sponsoring                    7000€
Operating expenses, which come to 146,813€ (-1.19% compared to 2013) are represented 92% by personnel costs (135,983€).
None of the other budgetary items have undergone significant variation.
Under these conditions the net result for 2014, after the financial result (870€), comes to minus (-) 4373€.

Having come to the end of the agenda: Each of the opinions or suggestions presented was duly recorded herein, and no expression of opposition was put forward. As the agenda had been exhausted, the session was adjourned.

 


Official record of the 22 August 2016 general meeting of the ARMGHM - Atlas of Genetics in cancer

Present or represented (having given a proxy) at the general meeting:  Jean Loup Huret, Président, Editeur de l'Atlas, Hossein Mossafa, Vice-Président, Bernard Drochon, Trésorier, Martine Jammet, Secrétaire, Philippe Dessen, Directeur de la Base de Données, Jean-Marie Nicolas, Paola Dal Cin , Katrina Vanura, Brenda Lauffart, Simona Panni, Mauricette Jamar, Christian Herens, Frédéric Lambert, Vincent Bours, Adriana Zamecnikova, Nathalie Nadal, Claude Viguié, Franck Viguié, Jacques Wintrebert.

Number of members whose subscriptions are duly up to date: 20. The quorum has been reached.

I- Annual moral and activity report

I-1. Administrative report

Due to a lack of reliably recurrent financial support, the Atlas had no choice but to separate itself from the publishing group, laying off 5 of its collaborators in March 2015.

Intensive lobbying was subsequently undertaken in view of developing permanent solutions ensuring continuation of the Atlas, which is highly appreciated by the cytogenetics community throughout the world (cf. http://atlasgeneticsoncology.org/Supporting_Atlas_First_signatories.pdf) with an average of more than 5000 visits a day; moreover, it has been conclusively shown that cytogeneticists,  whatever their countries, are highly regular users of the Atlas (cf. http://chromosomesincancer.org/fr/utilisateurs-de-l-atlas.html). Indeed, the Atlas has become a worldwide reference and a daily tool comparable to the "Mitelman".
Following exchanges with the scientific director of the French national cancer institute (INCa), François Sigaux, discussions were launched with John Libbey, the publisher. In addition, the Atlas dossier was quite favorably received by the Direction de l'Information Scientifique et Technique of the CNRS (DIST-CNRS) and by its director, Renaud Fabre, who mandated a commission to assess the possibility of joint backing from the CNRS and the INSERM. Finally, the INSERM Transfert branch evinced pronounced interest in the Atlas and tried to promote this interest with inter-organizational structures (ITMOs).
As of mid-2016, however, no solution providing lasting reassurance on the future of the Atlas had been determined, and discussions remained ongoing.
On the other hand, Vice President Hossain Mossafa obtained funding by means of sponsoring from the CERBA Institute.

I-2. Scientific report
The president/editor-in-chief Jean Loup Huret and the data manager Philippe Dessen have continued to not only update, but also develop new documents on the INIST site (CNRS Nancy).
Even without collaborators, the number of new or updated documents has remained distinctly significant: genes (33 new, 11 updated), leukemias (17 new, 3 updated), solid tumors (3 new), hereditary diseases and increased risk of cancer (3 new, 2 updated).
Substantive work has led to the preparation of lists of the different forms presently “on stand-by”, and the results are materialized in the pages accessible to authors (http://atlasgeneticsoncology.org/Status.html). Incidentally, at present the Atlas is the fruit of the labors of 3252 authors. 
Other work has consisted in providing increasingly precise definition of the classifications (in agreement with the WHO-ICD codes) (see the http://atlasgeneticsoncology.org/Anomalies/Anomliste.html and http://atlasgeneticsoncology.org/Tumors/Solid_Nosology.html) pages.
The “genes” pages of the Atlas has been expanded to cover the totality of the known and mapped genes of the human genome: all in all, 29333 genes.
Numerous links with new “cancer” portals (TCGA, ICGC ..) have been added to the forms and to the  synthetic tables, as well.
An ongoing large-scale endeavor has consisted in adding to the sections of the Atlas dealing with genes, leukemia and solid tumors a large number of references to the fusion of genes associated with chromosomal alterations; work on these subjects is also accessible in a grouping of more than 440 pages devoted to genes and abnormalities in all of the chromosomal bands (ex. http://atlasgeneticsoncology.org/Bands/1p36.html).
International activities have consisted in our participation on a workshop in Nijmegen, Holland (early 2016) and in our presentation of an Atlas tutorial (http://atlasgeneticsoncology.org/Nimegue_2016/Practical_exercise.pdf ). In addition, Jean Loup Huret has been asked to write a chapter on bioinformatics resources in cytogenetics (Springer editions, to be published in late 2016).
A number of Associate Editors, each of them in charge of a specific section,  have been named: "Lymphoma section Editor": Antonino Carbone (Aviano, Italy); "Urinary tumors Section Editor": Paola Dal Cin (Boston, Massachusetts); "Bone tumors Section Editor": Judith Bovee (Leiden, The Netherlands; " Cancer Prone Diseases Section Editor": Gaia Roversi (Milano, Italy). Other particularly talented colleagues have been or will be contacted.

II- Financial report
Following amortization, fixed assets are valued at 1€.
No movement was observed during the 2015 fiscal year.
Gross fixed assets valued before amortization at 80596€ consist mainly in a website valued at 72076€.
Current assets come to 36355€, including 31355€ of liquid assets on 31/12/2015.
Liabilities consist in normal and current debts and in provisions for accruals. The association has incurred no bank indebtedness.
Under these conditions and taking into account a deficit result amounting to 18134€, the net position of the association comes to 33424€.

Profit and loss account 2015
Operating revenue (45200€) is represented by: 
- grants              20347€
-donations and membership fees    16853€
-sponsoring                     8000€

Operating expenses come to 63434€ (-57% compared to 2014), and 90% are represented by personnel costs (56953€).
None of the other budgetary items have undergone significant variation. 
Under these conditions the net result for 2015, after the financial result (238€), comes to minus (-) 18134€. The 2015 fiscal year was characterized by the exceptional costs entailed by staff restructuring.

As of today, revenue in 2016 has come to approximately 2200€, while expenses have neighbored 1100€.
Grants from other learned societies that regularly support the Atlas have recently been requested; so has the backing of our sponsor.

III- Orientations for the 2017 fiscal year

Uncertainty about possible grant renewal has led us to entertain three hypotheses:
I- The possibility of hiring a collaborator holding a MSc on a one-year contract, at a cost of about 30000€, is predicated on our obtaining corresponding financing;
II- The possibility of hiring a service provider who would be in charge of elaborating an editorial data base, at a cost of 80000€, is likewise predicated on our obtaining corresponding financing;
III- In any case, we have decided to resume publication of our "Pdf Journal", which was suspended after April 2015, (see http://documents.irevues.inist.fr/handle/2042/15655 ). In the final analysis, this publication is a vital precondition for our being indexed by PubMed, Scopus, Embase, etc…, and indexation is itself of crucial importance in our search for articles to replenish the Atlas. As of now, even though the number of pages will have to be reduced because of the absence of editorial collaborators, we still have enough articles to complete the Journal. What we need is the expertise of a person who was once a collaborator of ours, and who has agreed to resume work with us on a part-time basis.  Costs for the employer would come to an estimated 5000€ a year.

Having come to the end of the agenda: Each of the opinions or suggestions presented was duly recorded herein, and no expression of opposition was put forward. As the agenda had been exhausted, the session was adjourned.

 


Official record of the board of directors meeting and general assembly of the 16 May 2017 of the ARMGHM association - Atlas of Genetics in Cancer


Present or represented (having given a proxy) at the general meeting: Jean Loup Huret, Président, Editeur de l'Atlas, Hossein Mossafa, Vice-Président, Philippe Dessen, Directeur de la Base de Données, Jean-Marie Nicolas, Paola Dal Cin,  Adriana Zamekenekofa, Julie Sanford Biggerstaff, Brenda Lauffart, Christine Disteche, Claus Kerkhoff, Lubomir Mitev, Charles Bangs, Dan Van Dyke, Detlef Haase, Fléchère Fortin and the "Association de Cytogénétique du Québec", Jean-Michel Dupont, Katrina Vanura, Gilles Nicolas, Marie-Christine Nicolas, Ivan H Still, Vincent Bours, Mauricette Jamar, Frédéric Lambert, John Swansbury, Jacques Wintrebert, Anthony Brouard, Bernard Drochon
27 adherents were present or represented, the quorum was reached.

I - 2016 MORAL AND FINANCIAL REPORT

I-1. Administrative report
Due to a lack of reliably recurrent financial support, the Atlas had no choice but to separate itself from the publishing group, laying off 5 of its collaborators in April 2015.

None of the discussions undertaken in late 2015 and 2016 led to the emergence of a permanent solution for the Atlas. However, following talks with the DIST of the CNRS and its director, R. Fabre, a consensus was reached: The Atlas will continue to be hosted on the site of the INIST (Institute of Scientific and Technical Information).

The activities of the Atlas during 2016 were the fruits of the labors of the president, J-L Huret (editor-in-chief) and P. Dessen (data base manager), thanks to whom a minimum level of production was maintained.

Recently, a financial grant enabled us to rehire, on a decidedly part-time basis, one of our collaborators, whose task has been to restart the “Journal pdf”, the scientific edition of the Atlas (see http://documents.irevues.inist.fr/handle/2042/15655). Following its suspension in March 2015, and as planned last year (see 2016 report), publication has been resumed. This is the indispensable precondition for being indexed by PubMed, Scopus, Embase, etc...; indexation is itself of crucial importance in our search for articles to replenish the Atlas.

Marie-Christine Bolinches and Bernard Drochon did not request renewal of their mandates. On an interim basis, Jean Loup Huret has replaced the treasurer (Bernard Drochon) and has been mandated to seek out a new treasurer.

I-2. Scientific report
Even without the 5 collaborators laid off in 2015, in 2016 the number of new or updated documents remained distinctly significant: genes (37 new), leukemias (69), solid tumors (16), hereditary diseases at increased risk of cancer (2), case reports (5).

Section Editors have been assigned in charge of different themes
Lymphomas Section Editor: Antonino Carbone (Aviano, Italy)
Myeloid Malignancies Section Editor: Robert S. Ohgami (Stanford, California)
Urinary Tumors Section: Paola Dal Cin (Boston, Massachusetts)
Bone Tumors Section Editor: Judith Bovee (Leiden, The Netherlands)
Head and Neck Tumors Section Editors: Cécile Badoual and Hélène Blons (Paris, France)
Pediatric Tumors Section Editor: Frederic G. Barr (Bethesda, Maryland)
Cancer Prone Diseases Section Editor: Gaia Roversi (Milano, Italy)
AKT signalings Section Editor: Robin C.Muise-Helmericks (Charleston, South Carolina)
Cell Cycle Section Editor: João Agostinho Machado-Neto (São Paulo, Brazil)
DNA Repair Section Editor: Godefridus Peters (Amsterdam, The Netherlands)
Hormones and Growth factors Section Editor: Gajanan V. Sherbet (Newcastle upon Tyne, UK)
Mitosis Section Editor: Patrizia Lavia (Rome, Italy)

Substantive work has led to the preparation of lists of files presently “on stand-by”, and the results are materialized in the pages accessible to authors (http://atlasgeneticsoncology.org/Status.html). Incidentally, at present the Atlas is the fruit of the labors of more than 3300 authors.  
Other work has consisted in improving classifications (in agreement with the relevant WHO-ICD codes) (see the http://atlasgeneticsoncology.org/Anomalies/Anomliste.html and http://atlasgeneticsoncology.org/Tumors/Solid_Nosology.html) pages.
Numerous links with new “cancer” portals (TCGA, ICGC ..) have been added to the files and updated; so have the synthetic tables.
An ongoing large-scale endeavor has consisted in adding references to the fusion of genes associated with chromosomal alterations (see the sections on Genes, Abnormalities and Solid Tumors); work on these subjects is also accessible in a grouping of more than 440 pages devoted to genes and abnormalities in all of the chromosomal bands  (ex. http://atlasgeneticsoncology.org/Bands/1p36.html).
In addition, Jean Loup Huret was asked to write a chapter on bioinformatics resources in cytogenetics (Springer editions, published in 2016).

II- Financial report
Overall summary
Fixed assets are currently fully depreciated.
No movement was observed during the 2015 fiscal year.
Gross fixed assets valued before amortization at 80596€ consist mainly in a website valued at 72076€.
Current assets come to 51814€, including  51575€ (???) of liquid assets on 31/12/2015.
Liabilities consist in  normal and current debts and in provisions for accruals. The association has incurred no bank indebtedness.
Under these conditions and taking into account a profit result amounting to 17789€, the net position of the association comes to 51214€.

Profit and loss account 2016
Operating revenue (21534€) is represented by:  
- grants              10823€
-donations and membership fees    2708€
-sponsoring                     8000€

Operating expenses come to 3978€  (as compared to 63434€ in 2016). Under these conditions the net result for 2016, after the financial result (233€), comes to 17789€.

III- Orientations for the 2018 fiscal year
Uncertainty about possible grant renewal has led us to entertain three hypotheses:
I- The possibility of hiring a “Bac+5” (= 5 years of university studies) collaborator on a one-year contract, at a cost of about 30000€, is predicated on our obtaining corresponding financing;
II- The possibility of hiring a service provider who would be in charge of elaborating an editorial data base, at a cost of 30000-60000€, is likewise predicated on our obtaining corresponding financing.

The agenda having been exhausted and with no opposition having been put forward, each of the views expressed has been officially enacted.
The agenda having been exhausted, the session is adjourned.


Minutes from the Executive board and General Assembly meetings of the Association ARMGHM - Atlas Genetics Cancer of the 16/05/2018

Executive board
Present or represented: Jean Loup Huret, President of the Association and Editor in Chief of the Atlas, Philippe Dessen, Database Director, Martine Jammet, Treasurer and Secretary of the association, Bernard Drochon, Franck Viguié, Jacques Wintrebert.
The Executive Board was informed that talks were engaged between the Atlas and Robert Ohgami (University of Stanford, California, now Co-Editor-in-Chief of the Atlas), Paola Dal Cin (University of Harvard, Boston, Massachusetts), and Jesús María Hernández Rivas (HARMONYproject/University of Salamanca, Spain). These three University Hospital researchers and educators are working to build a new web site for the Atlas. The Executive Board gave its agreement on the continuation of the talks, provided that a full description of what the aim, purposes, editorial line, layout and organization will be is given to the Association Board, inasmuch as the project remains vague.
The Executive Board also agrees to finance a database project on the basis of a detailed cost estimate.
An address modification will be sent to the prefecture. The new address: "ARMGHM, Chez Docteur Jean Loup Huret, 10 rue des Treilles, Masseuil, F-86190 Quinçay, Fance" will replace: "ARMGHM, Chez Docteur Jean Loup Huret, Faculté de Médecine, 6 rue de la Milétrie, BP 199, F-86034 Poitiers, Fance"

General Assembly
Present or represented (having given a proxy) at the general meeting: Jean Loup Huret, President of the Association and Editor in Chief of the Atlas, Philippe Dessen, Database Director, Martine Jammet, Treasurer and Secretary of the association, Adriana Zamekenekova, Anil Yadav, Bernard Drochon, Brenda Lauffart, Carole Barin, Christine Disteche, Chrystèle Bilhou-Nabera, Claude Viguié, Colette Drochon, Dana Bangs, Diane Jordan, Franck Viguié, Frédéric Lambert, Holly Hobart, Irwin Gelman, Ivan Still, Jacob Barnhart, Jacques Wintrebert, João Agostinho Machado-Neto, John Swansbury, Katrina Vanura, Lubomir Mitev, Marina Lafage, Mauricette Jamar, Nagesh Rao, Nyla Heerema, Paola Dal Cin, Rita Calzone, Robert Ohgami, Simona Panni, Tatiana Gindina, Tobias Neff, Vincent Bours, Virginie Eclache-Saudreau.
37 adherents were present or represented, the quorum was reached.

I- Moral and activity report 2017
In spite of the small number of workers in the day-to-day work in the Atlas (mainly Jean Loup Huret (President of the Association and Editor-in-Chief of the Atlas) and Philippe Dessen (Database Director), the scientific production has remained stable.

 

The Atlas is still hosted for free by the Institute for Scientific and Technical Information of the French National Center for Scientific Research (INIST-CNRS http://www.inist.fr/?lang=en) and there are 4500 visits each open day (period April-May 2018).

A substantive work has been to provide a list of items that will need to be developed as papers/cards (e.g. list of chromosome rearrangements/fusion genes, according to a given disease, where an expert will be needed to write a monograph).

Numerous links toward portals devoted to cancer (TCGA, ICGC ...) and databases (Mitelman database, COSMIC, ArrayMap ...) have been added and/or updated on the front page and within each page when relevant.

The data formatting process for the "Atlas Scientific Journal" (see http://documents.irevues.inist.fr/handle/2042/15655), following its suspension in March 2015, is now again in progress. A data processing program is being built up (web application developed with PHPWord/MySQL/Symfony framework), to facilitate and speed up the data formatting process, so that it will be up-to-date again. The "Atlas Scientific Journal" is also frequently viewed.

A set of pages devoted to molecular and cellular biology, and to pathogeny (grouped into different thematics e.g. apoptosis, immunity …) make a census of genes involved in these processes. These thematics are being developed, and some of these have been covered by dedicated "Section Editors" (see: http://atlasgeneticsoncology.org/BackpageAbout.html#EDITORIAL). More Section Editors have been co-opted, to strengthen our Editorial task force.

The association's address will change.

Robert Ohgami (University of Stanford, California) has become Co-Editor-in-Chief of the Atlas.
Robert Ohgami, Paola Dal Cin (University of Harvard, Boston, Massachusetts), and Jesús María Hernández Rivas (HARMONYproject/University of Salamanca, Spain) are working to build a new web site, with a new home page, new data and updates, incorporating NGS data and other developments, such as "big data". A new database is necessary, using universal tools and free softwares.

The establishment of a database/web site and computer-assisted editorial process production have been made possible by the donations from the following Scientific Societies: Association des Cytogénéticiens de Langue Française, Berufsverband Deutscher Humangenetiker / Deutschen Gesellschaft für Humangenetik (BVDH/GFH), Werkgroep  Hemato-oncologische Genoom Diagnostiek (WHGD), Società Italiana di Genetica Umana (SIGU), Australasian Society of Cytogeneticists (ASOC), Association de Cytogénétique du Québec (ACQ), Canadian College of Medical Geneticists.
Funding requests will be sent in 2018 as well to these Scientific Societies to enable us to pursue the development of the new database (Orientations for the 2018 fiscal year).

II- Financial report 2017

II-1. Balance sheet statement
The capitalized asset is completely depreciated.
No movement was observed during the 2017 fiscal year.

Gross fixed assets valued before amortization at 72,363€ consist mainly in a website valued at 72,076€.
Current assets come to 65,198€, all of them are liquid assets at the date of December the 31st, 2017.

Liabilities consist in normal and current debts and in provisions for accruals. The association has incurred no bank indebtedness.
Under these conditions and taking into account earnings of 12,459€, the net position of the association comes to 63,673€.

II-2. Profit and loss account 2017
Operating revenue (45,200€) is represented by:
- grants: 10,432€
- donations and membership fees: 2,396€
- sponsoring: 8,000€
Operating expenses come to 8,660€ (3,978€ in 2016).
Under these conditions the net result for 2017, after the financial result (+302€), comes to plus (+) 12,459€.

II-3. Orientations for the 2018 fiscal year
(see above).

Having come to the end of the agenda: Each of the opinions or suggestions presented was duly recorded herein, and no expression of opposition was put forward. As the agenda had been exhausted, the session was adjourned.


Official record of the board of directors meeting and general assembly of the 22/06/2019 of the ARMGHM association - Atlas of Genetics in Cancer


Executive board
Present or represented: Dominique Penther, Fléchère Fortin, Franck Viguié, Hossein Mossafa, Jean Marie Nicolas, Lucienne Michaux, Marina Laffage-Pochitaloff, Philippe Dessen, Philippe Misserey, Jacques Wintrebert, Jean Loup Huret, Martine Jammet
General Assembly
Present or represented (having given a proxy) at the general meeting: Dominique Penther, Fléchère Fortin, Franck Viguié, Hossein Mossafa, Jean Marie Nicolas, Lucienne Michaux, Marina Laffage-Pochitaloff, Philippe Dessen, Philippe Misserey, Jacques Wintrebert, Jean Loup Huret, Martine Jammet, Anil Yadav, Claude Viguié, Dana (Charles) Bangs, Diane Jordan, Ivan Still, Katrina Vanura, Lubomir Mitev, Nathalie Nadal, Nyla Heerema, Tatiana Gindina
22 adherents were present or represented, the quorum was reached.

Scientific Report Year 2018
The activity of the Atlas during 2018 was the result of the work of President J.L. Huret (editor-in-chief) and P. Dessen (database manager) to maintain a minimum level of production.
In spite of its very limited strength, the Atlas has managed to maintain itself through a significant production of new documents or updates. The Atlas is still hosted on the INIST-CNRS site and continues to have significant visibility (international consultation).
In order to improve production and quality, the Atlas has continued to add several "editors' sections" that have taken on various specialties.
The Atlas-Journal, which is widely consulted on the INIST website, is currently up to date.
Finally, as part of a transition of the Atlas to an international consortium with scientists from Stanford, Boston or Salamanca, a new version of the more "modern" Atlas is being developed at the University of Salamanca. This has led to a fairly large amount of work to formalize the structures and software developed over the last 20 years, in order to designate the new base more easily.
The end of 2019 should see the commissioning of this new tool.

Financial Report - Balance sheet 2018
For the 2018 financial year, a sum of €2,313 has been recorded as fixed assets, corresponding to two down-payments for the development of the website.
The gross fixed assets (before depreciation and amortization) amounting to 76,433€ are mainly comprised of the website for 74,389€.
Current assets amounted to €61,129, including €61,129 in cash and cash equivalents at 12/31/2018.
Liabilities consist of normal and current debts and provisions for accrued expenses. The association does not have recourse to any bank debt.
In these conditions and taking into account the profit of 190€ the net situation of the association amounts to 63 863€.
Income Statement 2018
The operating revenues (10 583€) are represented :
-by subsidies 6 000 €
-by donations and contributions 4 576 €
-other miscellaneous products 7 €
Operating expenses amounted to €10,805 compared to €8,660 in 2017. As a result, net income for 2018, after financial income (€412), was €190 higher.


Official record of the board of directors meeting and extraordinary general assembly of the 13/12/2019 of the ARMGHM association - Atlas of Genetics in Cancer


Excerpts from the Minutes of the Board of Directors and the Extraordinary General Meeting
Present or represented having given proxy to the Board of Directors: Dominique Penther, Fléchère Fortin, Franck Viguié, Hossein Mossafa, Jean Loup Huret, Jean Marie Nicolas, Lucienne Michaux, Marina Lafage-Pochitaloff, Martine Jammet, Philippe Dessen, i.e. 10 of the 11 members of the Board of Directors.
Present or represented and having given proxy at the Extraordinary General Meeting: Dominique Penther, Fléchère Fortin, Franck Viguié, Hossein Mossafa, Jean Loup Huret, outgoing President, Jean Marie Nicolas, Lucienne Michaux, Marina Lafage-Pochitaloff, Martine Jammet, outgoing Treasurer, Philippe Dessen, Philippe Misserey, Ana Rodriguez, Anil Yadav, Atieh Hajianpour, Baptiste Gaillard, Claude Viguié, Charles Bangs, Diane Jordan, Ivan Still, Jesùs Maria Hernandez-Rivas, Joao Agostinho Machado Neto, Katrina Vanura, Kay Huebner, Lubomir Mitev, Margaret Booth, Nathalie Nadal, Nyla Heerema, Olgierd Ossowski, Roberto Rosati, Silvia Soriani, Simona Panni, Tatiana Gindina
That's 32 members. A quorum is present.

Election of a new President, a new Treasurer, and a new Secretary:
We announce the resignation of Martine Jammet and Jacques Wintrebert from their positions as Directors and note their replacement by Jesús María Hernandez Rivas and Ana Eugenia Rodriguez Vicente (Salamanca, IBSAL); and the resignation of Jean-Loup Huret from his position as President. We vote that Jesús María Hernandez Rivas be elected President, Ana Eugenia Rodriguez Vicente be elected Secretary and Jean-Loup Huret be elected Treasurer of the association.

The devolution of the Atlas to IBSAL was decided as well as the creation of an Atlas database in Salamanca to replace the current site, with data transfer to the new site. The new site will now have 3 Chief Editors: Jean-Loup Huret (Genes), Jesús M. Hernández (Haematology), and Paola Dal Cin (Solid Tumours).

These resolutions are adopted by the 10 members of the Board of Directors, and voted by the Extraordinary General Assembly by 32 votes in favour, 0 abstentions, 0 votes against.

The agenda having been exhausted: Each of the opinions expressed has been recorded herein and no remarks have been made against it. The agenda having been completed, the meeting is adjourned.

The Chairman of the meeting
Jean-Loup HURET

Confidentiality

Preamble

The association ARMGHM's goal is to host and handle the Atlas of Genetics and Cytogenetics in Oncology and Haematology (AtlasGeneticsOncology.org), to facilitate the editorial process and to permit the circulation of its content. To be worthy of the confidence
of our past, present and future donors in all circumstances is a priority forus.

Therefore, the association has defined a personal data management policy concerning our donors rights and our commitments towards them. In particular, this policy defines the rules governing confidentiality applicable to this matter, which will regularly be updated by our board of directors.

Donors' Rights

The association acknowledges that our past, present and future donors have the following rights:

  • being informed of the goals of the association, of the way the association intends to use donated resources, and of its capacity to use donations effectively for their intended purposes;
  • being informed of the identity of the members of the board of directors of the association;
  • expect the board to manage the funds collected by the association cautiously;
  • have access to the most recent financial reports of the association;
  • be sure that their gift will be used for their intended purposes;
  • be sure that their personal data will be handled with confidentiality within the limits of the applicable legal regulations for data protection in France;
  • receive appropriate acknowledgement and recognition;
  • at any time, on simple request to the association, have access to the data and may request that it be changed, rectified or deleted;
  • being informed of  the quality of the people soliciting donations: volunteers, employees of the association, funds raising companies;
  • be able to ask any question, and receive, quick, honest and direct answers.

Policy followed by the association

  • Collection and storage of personal data

For each donation, the association collects and stores informations concerning the donor, namely his/her name, first name, and email address. The donor can also provide his/her mailing address, and, whenever appropriate, the name of the company and its business identification number ("SIRET" in France). Along with these personal informations, is data on the donation itself, including its amount.

All these informations are for the sole use of the association ARMGHM. According to  the articles 39 and 40 of the french law "Informatique et Libertés" (data processing and privacy) n°78-17, january the 6th, 1978, donors have at any time, a right of access, rectification and opposition to all of their personal data.

No donation shall be publicly announced by the association ARMGHM without the donor's specific agreement.

Transactions made on the platform for online payment using credit cards are secured through PayPal payment system. all informations exchanged with the payment server are encrypted using the SSL protocol and cannot be intercepted, reused or changed by third parties. They are neither kept on our computers.

Comments provided by telephone e-mail shall remain strictly confidential.

  • Use of the data

Donors personal data is used exclusively within the association ARMGHM. No one else than members of the board of directors, and volunteers or staff authorised the board of directors can have access to this data.

The association requests an absolute confidentiality of service providers and external collaborators helping the association to achieve its mission, in the case they would have access to donors personal data.

The association uses the donors personal data, including their postal and e-mail addresses only in the following cases:

  • to send a fiscal receipt, corresponding to their donation,
  • to thank donors,
  • to inform donors of forthcoming fund raisings and any of the association's activities,
  • to fulfil its obligations towards the public authorities and the french state,
  • to contact donors regarding any changes to this policy.

The association shall not publish, sell, license, exchange, trade or share any personal data of donors.

Nonetheless, the association may use or release data rendered anonymous, in particular as part of its promotion-related or fund raising activities. As an example, data may be used o establish statistics on the amounts collected or on the geographical origin of donors of the association.

Contact us

If you have any question concerning our personal data management policy, please, contact us:

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: +33 5 49 44 45 46

Donate now!

  • by credit card, on our platform for secure online payment using PayPal:

Donate (in Euros)

Donate (in US Dollars)

  • by cheque, to be sent to:

Association ARMGHM, Chez Dr JL Huret, Génétique, Dept d'Information Médicale, CHU La Milétrie, 86021 Poitiers.

 

How to contact us

Dr Ana E. Rodríguez,

Association ARMGHM
E-mail : This email address is being protected from spambots. You need JavaScript enabled to view it.

Tax deduction


The association ARMGHM is a french non-profit association, governed by the french law "1901"; being recognized as a "general interest association", it has been found eligible for the allowance of tax deduction mentioned in articles 200 and 238 bis of the general tax code.

  • Deduction of 66% for an individual donor in France (see the regulations in your own country). A donation of 30 € will cost you only 10,20 € and a donation of 100 € only 34 € after tax deduction.
  • Deduction of 60% for a company (if you have a subsidiary in france).
    •  A donation of 1 000 € will cost you only 400 € after tax deduction.
    •  A sponsoring of 20 000 € will cost you only 8 000 € after tax deduction.

If you need a fiscal receipt, we will send it to you in PDF format, by e-mail preferably, as soon as we can; this will take a few days or weeks. In the case you do not receive anything, or for any question, please do not hesitate to contact us.

Scientific Journals

Scientific Databases

Scientific Societies

Please see the following: Call to help the Atlas 2015

 

Nominated for an Award! The Atlas was nominated (...but did not win) for an Award, from the American Society of Human Genetics



Colleagues

A bug, on May the 23rd, 2008...

A bug, on May the 23rd, 2008, was devastating: pages on chromosomes, with their data, had vanished; many mails were sent to us, proving that the Atlas was (is) indispensable.
Some of these mails are in this hyperlink.

 


 

Scientific Journals

  • Nature Reviews Cancer

"The database provides an enormous amount of information in a user-friendly format"

  • Science

"A wealth of information on these mutations can be found at the Atlas of Genetics and Cytogenetics in Oncology and Haematology, a peer-reviewed site…"

  • Nature science update

"The field of cancer is vast, that of genetics gigantic. Combine the two and researchers risk data overload. (…) With contributors across Europe and the United States, Huret is collating the ever-expanding body of information on cancer-implicated genes into the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
It’s a huge task (…)
"It will never be complete" says the man who has a ‘Work in Progress’ road sign on his site. (…)"

Audience of the Atlas: Papers published in the Atlas are cited as such in:

  • Annual Review of Biochemistry (Impact Factor 29,88),
  • Science (29,75),
  • Nature Reviews Cancer (29,54),
  • Cancer Cell (25,29),
  • Nature Cell Biology (19,53),
  • Journal of the National Cancer Institute (14,07),
  • American Journal of Human Genetics (12,30),
  • Molecular Systems Biology (12,13),
  • Genes and Development (12,08),
  • Genome Research (11,34),
  • Trends in Molecular Medicine (11,05),
  • Blood (10,56),
  • Proceedings of the National Academy of Sciences USA (9,43),
  • Trends in Genetics (8,69),
  • Leukemia (8,30),
  • Cancer Res (7,54),
  • Nucleic Acids Research (7,48),
  • Oncogene (7,13),
  • … and many others

 

 

Scientific Databases

  • Jon Teague, Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK

"I think it would be very useful feautre for COSMIC/CENSUS to link to the peer reviewed reports of cancer genes from "The Atlas Genetics and Cytogenetic in Oncology and Haematology". Personally, I find the Atlas a great resource and use it on a weekly basis."

  • Amos Bairoch, Swiss-Prot group, Swiss Institute of Bioinformatics, CMU, Geneva, Switzerland

"It has been a while (2002!) since I have been in contact with you and Philippe Dessen about the links from Swiss-Prot to your wonderful Atlas."

  • Jaime Prilusky, GeneCards Head Bioinformatics Unit, Weizmann Institute of Science, Rehovot, Israel

"Your site is quite interesting and provides useful information that we will be glad to link into from GeneCards."

  • Fan Hsu, UCSC Genome Project, University of California, Santa Cruz, CA

"I would like to explore the possibility of collaboration with your organization on building an annotation track for UCSC Genome Browser based on your data collection.
(Currently we don't have a specific "Cancer Related Genes" track, but I am very interested in exploring the possibility of building one. Putting this track with other tracks we already have, e.g. NCI60 cell line microarray data, may help our fellow researchers to find cure to cancers sooner. I have built a prototype "Immunology Related Genes" track before while I was taking an Immunology class. So technically this is definitely possible, given someone can provide us a credible set of gene list and associated data, e.g. descriptions, links, xref to other resources, etc. I will try to contact the "Atlas of Genetics and Cytogenetics in Oncology and Haematology" group to see if they are willing to share their data to enable us to build a track like that. Fan Hsu, UCSC)"

  • James Testa, Editorial Development, Thomson ISI

"Greetings! You are publishing important, high-quality material on the Web. For this reason, ISI has selected your site http://www.infobiogen.fr/services/chromcancer/index.html for inclusion in Current Web Contents."

 

Scientific Societies

  • European Cytogeneticists Association

"Your letter was discussed at the last ECA executive board session. We decided to support your database which is very helpful for medical geneticists."

  • Groupe Francophone de Cytogénétique Hématologique (French Cytogenetics Society)

(Translation) "The board of the GFCH has given a favourable judgment towards the Atlas. This internationally known web site, created by a member of the GFCH, is very useful for physicians working in the field of the genetics of malignant blood diseases."

  • Société Française du Cancer (French Cancer Society)

(Translation) "The SFC is particularly interested by Atlas, because it is at the convergence of the interactive post-university education, the research and, of course, the cancer treatment […] This database on the cytogenetic of cancers comes especially in opportune moment where, as we know, many hundreds of genes are implicated in cancer and that we are, through this tool, on the eve of an emergence of a new classification for organism cancers.
Therefore, the SFC without reserve decided to support this encyclopaedia […] The remarkable work achieved by J-L Huret to maintain this website merits not only to be perpetuated but to be developed more (by mobilizing new human energies and by contributing fundamental financings, not only for maintaining it, but for developing it).
For its part, the SFC will encourage its members to be mobilized for this project."

  • Société Française de Génétique Humaine (SFGH) et Société Française de Génétique (SFG) - (French Society of Human Genetics and French Society of Genetics)

(Translation) "… the Société Française de Génétique and the Société Française de Génétique Humaine wish to testify their support on Mr J-L Huret's action in the maintaining of the http://www.atlasgeneticsoncology.org Website. This site, entitled: Atlas of Genetics and Cytogenetics in Oncology and Hematology, is of high quality, at once appreciated by physicians, biologists and researchers in cancer and haematology domains. A colossal work had been done by Mr Huret and the survival of this work tool, precious for numbers of French and European professionals, depends exclusively on him. A constant effort is necessary to integrate new information and to regularly update the documents already online. This cannot be done without financing and human supports that our two Learned Societies call without reserves of their wishes."

  • Société Française d’Hématologie (French Hematology Society)

(Translation) "On the name of all the Sociéte Française d’Hématologie members, I wish to support strongly Dr Huret action for maintaining and developing the entitled Website: Atlas of Genetics and Cytogenetics in Oncology and Hematology. It is a remarkable work, containing information of a great value. A financing support to perpetuate this work has to be set up…"

  • Institut National du Cancer (French National Institute for Cancer)

(Translation) "… Allow me first to congratulate you for the achieved work that I could note the quality when I visited your Website […] once again, I would congratulate you for the work done and I hope that you could find the means for the website development"

 

Colleagues

  • Felix Mitelman, University Hospital, Lund, Sweden

"I must say that I am very impressed by what I have seen. It is very well organized and structured, easy to use, and informative. I am sure that it will be extremely useful for all of us. I will be delighted to have an opportunity to contribute to this important work. "

Support Letter, 2011

  • Lidia Larizza, Department Medicine, Surgery and Dentistry, University of Milan, Italy

Support Letter, 2011

  • Peter Vandenberghe, University Hospital Leuven, Leuven, Belgium

Support Letter, 2011

  • Nadine Van Roy, Center for Medical Genetics, Ghent University Hospital - UZGent, Gent, Belgium

"We also make daily use of the information that is stored in the Atlas database and it would be a great loss if this database would be discontinued. I am convinced that a lot of other Belgian and other European cytogeneticists think about it in the same way."

  • Christian Herens, Department of Human Genetics, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium

"The atlas is very useful in my daily practice (onco-haematology cytogeneticists). The Atlas provides numerous informations concerning chromosome anomalies with diagnosis, prognosis , genes involved and the molecular consequences. Despite more than 3000 cases a year, we are regularly confronted to rare or never viewed anomalies. In the great majority of these cases, the atlas brings us a near complete overview of the informations we need."

  • Pascaline Talmant, CHU de Nantes, France

"J'admire beaucoup le travail que tu as fait sur ce site, que tu as monté et défendu contre vents et marées ...."

"... la qualité du travail réalisé jusqu'à présent, qui nous rend tant de service au quotidien, et qui mérite d'être poursuivi et mener longue vie."

  • Marina Lafage, Université de Marseille et CHU la Timone, Marseille, France

"...cet Atlas que je consulte très régulièrement et dont j’apprécie particulièrement la facilité d’utilisation et la qualité des fiches rédigées par nos collègues qui font référence dans les pathologies concernées."

  • Chrystèle Bilhou-Nabera, Université Paris Sud et CHU Le Kremlin Bicètre, France

"J'ai une grande admiration pour le travail que tu as réalisé en toute discrétion et sans la reconnaissance académique que tu mérites grandement. L'équipe et moi-même pensons à toi tous les jours car nous nous servons quotidiennement de cet outil."

  • Claude Viguié, CHU Cochin, Paris, France

"Ton travail est indispensable pour de nombreux généticiens et j'admire ton énergie et ta ténacité pour faire vivre l'Atlas."

  • Nick P. Bown, National Health Service (NHS) Northern Genetics Service, Newcastle upon Tyne, UK

Support Letter, 2012

  • Katherine Martin, Department of Cytogenetics, City Hospital Campus, Nottingham University Hospitals, Hucknall Road, Nottingham, UK

Support Letter, 2012

  • Fiona Ross, Head of Oncology, Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK

"I am writing in support of the Atlas of Genetics and Cytogenetics in Oncology and Haematology. This is an invaluable resource for cytogeneticists, both in daily practice and in training. One of the features that makes this a particularly effective resource is that the abnormalities come with pictures. This is extremely helpful to help decide whether something rare that has just come through the lab really is the same as other reported cases or not and is invaluable in preparing trainees for what to be on the lookout for. The collected information also saves hours of time, sorting through publications for significance of abnormalities. It would be a very great loss to the cytogenetics community worldwide to lose this resource."

  • Polly Talley, The Children's Hospital Sheffield Western Bank, Sheffield, UK

"My name is Polly Talley and I am deputy of the Oncology section in the genetics department in Sheffield, England. I have received information from Prof Christine Harrison with regard to funding for the Atlas database. I am writing to support the continuation of this resource. We use this database on a regular basis, several times per week and find this a crucial and very useful starting point. I am aware that some pages are a little out of date, and would support not only the continuation, but also the updating of this site. We also use the site for training purposes and the image representation is extremely helpful, particularly for those abnormalities we do not see on a frequent basis. I hope you can use this letter of support to demonstrate the need for continuation of funding for this important resource."

  • John Swansbury, Clinical Cytogenetics Laboratory, The Royal Marsden Hospital and the Institute of Cancer Research, Sutton, Surrey, UK

"This email is to let you know that we in this laboratory find the Atlas to be very helpful. We refer to it a few times every week, particularly when we have a case with unusual cytogenetic abnormalities. It is a large collection of information and we appreciate that it must take a lot of time and effort to keep it relevant and up-to-date. Here in the UK we have two large collections of cytogenetic data. One is the huge national collection of Trials data that is managed by Christine Harrison, and which has been funded for twenty years by Leukaemia Research. The other is a large collection of unselected laboratory data held by the Cytogenetics Unit in Oxford, managed by Claire Scott, and which is known as the CAD. This had funding for a few years but it eventually came to an end. Consequently that collection is no longer maintained or updated. I mention this as an example of how important it is to get long-term secure funding for shared resources. Without these resources, each laboratory has to work in isolation without the benefit of the information gained in other laboratories, and there is a risk that clinical management of patients may be adversely affected."

  • Sally Jeffries, West Midlands Regional Genetics Laboratories (WMRGL), Birmingham Women's NHS Foundation Trust, Birmingham, UK

Support Letter, 2012

  • Janet D. Rowley, University of Chicago Medical Center, Illinois

"I have logged on to your Website and find it very useful. In the future I will undoubtedly rely on your Website rather than trying to keep up with the literature myself. Good luck on continuing this important service to the community."

  • Charles Bangs, Cytogenetics, Stanford Hospital, California

"I am compelled to tell you how extraordinarily useful I find the Atlas. I refer to it regularly and find it a tremendous resource. Thanks to you and your contributors for what is clearly an enormous amount of work."

  • Siddharth G. Adhvaryu, Cytogenetics Laboratory, San Antonio, Texas

"I wanted to congratulate you on this excellent database. It helps a lot in keeping us with the developments in the field. Thank you so much for making it available on web (...). I wanted to convey my gratitudes for such an excellent resource you have provided to the Cytogenetics Community. I have been using this resource on almost daily basis."

  • Oskar A. Haas, Children’s Cancer Research Institute, Vienna, Austria

"I just had a look at your website. A marvellous undertaking. Congratulation to the work you have already done. I think this website will become very important for cytogeneticsts working with tumors and leukemias.
(…) the website, which we all use a lot and appreciate. It is certainly one of the biggest help in our every day work. You have done a marvellous job."

  • Claudia Schoch, Labor für Leukämie-Diagnostik, München, Germany

"Your atlas, a reference for a lot of people involved in the cytogentics field. We greatly appreciate your work. The Atlas is a current tool in our lab."

  • Jesus M. Hernandez Rivas, Citogenetica Oncologica, Hospital Universitario de Salamanca, Spain

"Your atlas, a reference for a lot of people involved in the cytogentics field. We greatly appreciate your work. The Atlas is a current tool in our lab."

  • Maggie Fitchett, Oxford Medical Genetics Laboratories, Oxford, United Kingdom

"I have now managed to access your website. I am very impressed! This is just what we need, especially for the more unusual abnormalities."

  • Elizabeth M. Petty, Division of Medical Genetics, Ann Arbor, Michigan

"I am a familiar with the Atlas and use it a lot."

  • Malcolm Parslow, Department of Laboratory Medicine, Victoria General Hospital, Victoria, Canada

"I have just recently discovered this Atlas on the web. It is wonderful."

  • Adrian T. Sumner, North Berwick, United Kingdom

"Thank you for inviting me to contribute to the website (which I have to say, is easily one of the best I have visited)."

  • Elena W. Fleischman, Russian Cancer Research Center, Moscow, Russia.

"Wish to express to you my immense gratitude for the creation of the Atlas. Your Atlas is excellent creature. It is so useful for physicians, cytogeneticists and for me personally"

  • Peter D. Aplan, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

"I looked at the web page for the first time today (I hadn’t known of it’s existence), and found it to be incredibly useful (and complete). I’m grateful that you have taken the time and effort to develop such a page."

  • Mariano Rocchi, Istituto di Genetica, Bari, Italy

"I would like to stress that your site is really wonderful."

  • Roberta Vanni, Scienze Applicate ai Biosistemi, Calgari, Italy

"The Atlas is useful and easy to consult both for expert people (including pathologists), but also for students approaching genetics and cytogenetics in oncology."

  • Nyla A. Heerema, Department of Pathology, The Ohio State University, Colombus, Ohio

"Your Atlas is wonderful. It is a very useful site."

  • Charles H.C.M. Buys, Department of Medical Genetics, Groningen, The Netherlands

"With admiration for and appreciation of your efforts to consolidate the Atlas."

  • Nagendra K. Prasad, Purdue University, West Lafayette, IN 47907, USA

"Many thanks for this opportunity to participate in your wonderful effort to serve the cancer community."

  • Aurelia Meloni-Ehrig, Associate Editor Cancer Genetics and Cytogenetics, Quest Diagnostics Nichols Institute, Chantilly, VA 20151, USA

"I will definitely keep in mind the offer to contribute some articles. This is a wonderful web site and we all should contribute to it. Thanks for doing such a great job."

  • Kerry Rhoden, Universita di Bologna, Bologna, Italia

"I learned of the Atlas of Genetics and Cytogenetics in Oncology and Haematology from a colleague, Dr. Giovanni Tallini, and find it a very interesting and useful database."

  • Tae Sung Park, Kyung Hee University College of Medicine, Seoul, Korea

"We really want to contribute to your website. Actually we got many help from your website."

  • Adam C. Smith, Hospital for Sick Children, Toronto, ON. Canada

"Firstly I wanted to mention that I really enjoy your site and find it a tremendous reference."

  • Archibald Perkins, University of Rochester, Rochester NY, USA

"I'd like to complement you on this database - it is a fantastic resource that gets constant use by our hematopathology team."

  • "chris"

"I just wanted to tell you that i find the atlas pages incredibly informative, and i enjoy browsing your documents on your site. i stumbled upon your site googling information about head and neck SCC, and found the following link: http://atlasgeneticsoncology.org/Tumors/HeadNeckSquamID5090.html i just wanted to say that i think it's a great site, even for the layman to browse. i survive my father after his one year fight with head and neck cancer, and have been working on a SCC dedicated website. nothing else to this email, i just felt compeed to exclaim my appreciation for your site."

  • Yi-Hong Zhou, University of California, Irvine, CA 92697, USA

"I think the Atlas is a great resource for both basic and clinician."

  • Hope H. Punnett Harvard Medical School, Children's Hospital Boston, Boston, MA, USA

"Thank you for all the information. It is a great resource."

  • Simon Cotterill, University of Newcastle, Royal Victoria Infirmary, Newcastle, UK

"Congratulations on your wonderful web site."

  • Kenneth McMilin, Alabama and Central Gulf Coast Region, American Red Cross Blood Services, USA

"Your Atlas is a wonderful resource. Indeed, I think it is an essential resource and I am delighted that it is on the internet, available world wide."

  • Javier S. Castresana, Universidad de Navarra, Pamplona, Spain

"I congratulate you for the works you are doing in the Atlas. It is great for cancer researchers."

  • Pierre-Henri Gaillard, Institut de Biologie Structurale et Moléculaire - CNRS, Marseille, France

"Le site atlasgeneticsoncology.org est formidable!"

  • Marie-Joelle Mozziconacci, Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Marseille, France

"L'Atlas est pour moi un précieux outil de travail."

  • Robert Stern, Al Quds University, Jerusalem, Israel

"... your magnificent and daunting effort. It is indeed a major task to organize all of this information. These are major contributions to the literature, and a great service to the medical and biological communities."

  • Nicole L Chia, ACT Pathology, Canberra Hospital, Woden, Australia

"I am an avid user of your website... Your website is a valuable asset and used by our lab and the haematologists daily."

  • Hayyam Kiratli, Hacettepe University School of Medicine, Ankara, Turkey

"I thank you cordially for inviting us to contribute to your magnificent e-atlas (...). We certainly feel privileged to cooperate with you. Once again thank you so much for allowing us to contribute to the Atlas."

  • Anita L Hawkins, Johns Hopkins Laboratory Baltimore, Baltimore, MD, USA

"Thank you for your continued work with the excellent Atlas!"

  • Sven Meuth, University of Wuerzburg, Würzburg, Germany

"Your Atlas of Genetics and Cytogenetics in Oncology and Haematology is a very important research tool for a number of researchers."

  • Shuho Semba, Kobe University Graduate School of Medicine, Japan

"Thank you for asking me to contribute to the Atlas of Genetics and Cytogenetics in Oncology and Haematology. I think it a great honor to take part in such a big project."

  • Dongfeng Tan, MD Anderson Cancer Center, Houston, TX, USA

"... your progressive and impressive journal."

  • Rosalyn Slater, Erasmus University, Rotterdam,The Netherlands

"I think that your web site is an excellent idea and is a source of very useful information."

  • Silvia Jimenez, Swiss-Prot group, Swiss Institute of Bioinformatics, Geneva, Switzerland

"I've always really appreciated your resource."

  • Malcolm Parslow, Victoria General Hospital, Victoria, Canada

"I have just recently discovered this Atlas on the Web. It is wonderful and I just wanted to send an email to say how much we appreciate having such a resource freely available. My hematopathologist colleague is ecstatic about it now I have shown it to him. Thank you."

  • Maxine Sutcliffe, Departments of Pathology and Pediatrics, All Children's Hospital/University of South Florida, St Petersburg, Florida, USA

"This is an excellent informative and useful first line resource. Please continue to build and expand in both leukemias and solid tumors. My work is principally pediatric tumors and there is much more to learn."

  • Lynne Abruzzo, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

"Your website is invaluable! As a cancer cytogenticist, signing out my cases would be infinitely more difficult without it. Thank you! Best wishes."

  • Virginia C. Thurston, BayCare Laboratories, Tampa, Florida, USA

"You are doing a wonderful job!"

  • Xia Li, AmeriPath Northeast, Shelton, Connecticut, USA

"I visit this site everyday when I sign out cases. This site is extremely useful for me. I am glad to see the updated information each day."

  • Jamur Valderez Ravaglio, Laboratory of Cytogenetics, Hospital de Clinicas/UFPR, Parana, Brazil

"The team of the Laboratory of Cytogenetics from Hospital de Clinicas/UFPR, Paraná, Brazil use this site every day and we recommend it to the doctors of the hospital. For us this site is veru useful and it aid us a lot!"

  • Manuel Avalos, Servicio de Genética Hospital Pediátrico, Corrientes, Argentina

"Very interesting tool to study relationship between microscopic findings and clinical aspects. Many coments are a big help to inform clinicians about cytogenetic results."

  • Jerome Loew, Rush University Medical Center, Chicago, Illinois, USA

"This is the most useful resource I know for genetic abnormalities in hematologic neoplasms."

  • Adriana Zamecnikova, Kuwait Cancer Control Center, Shuwaikh, Kuwait, Kuwait

"I want to thank to Atlas for the well designed and highly professional content. I am using the Atlas for my daily work in the field of cancer genetics, and the Atlas can be very usefull to various health professionals, such as geneticists, scientists, hematologists, oncologist.,,,"

  • Mauricette Jamar, Department of Human Genetics, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium

"An important tool for oncohemato-cytogenetics impossible to work without it !!"

  • Marian Stevens-Kroef, Universitair Medisch Centrum St Radboud, Dept. Human Genetics, Nijmegen, The Netherlands

"Since many laboratories have interest in further automation of interpretation of array data, we believe that web-based access to gene-databases such as your very valuable Atlas of Genetics and Cytogenetics will become common practice."

  • Joan Oliva, Department of Hematology, LA Biomed, Torrance, USA

"Thank you to give us the opportunity to write a paper for your prestigious journal."

  • Vito Pistoia, Laboratory of Oncology, G. Gaslini Institute, Genova, Italy

"The Atlas appears to be outstanding and a very useful tool for researchers."

  • Sainan Wei, Michigan State University, East Lansing, MI, USA

"This is very good resource for laboratory directors and academic researchers."

  • Elvira DRP Velloso, HCFMUSP, Eneas de Carvalho Aguiar, Sao Paulo, Brazil

"We like very much this friendly site. I always recommend this for my students. We also publish our cases with rare translocations in hematological diseases. "

  • Molly Parkman, Mayo Foundation, Rochester MN, United States

"I think this is a great website. Clearly it is a lot of work to maintain."

  • Nagesh Rao, Pathology and Lab Medicine, and Pediatrics David Geffen UCLA School of Medicine Los Angeles, CA 90024

" I have been a regular visitor to the ATLAS website and have also directed several residents/Fellows to visit for future reference. I would like to donate some money for the website maintenance etc."

  • Marianne Fertons, Centre Universitaire de Génétique, CHU - Sart Tilman, Liege, Belgium

" Le service de génétique du CHU de Liège (Belgique) souhaiterait faire un don à l'Association pour soutenir l'Atlas du Cancer."

  • Jennifer J.D. Morrissette, Department of Pathology, University of Pennsylvania, Philadelphia, PA

" The cytogenetics community in the US is interested in ways to help fund maintenance of your site."

  • Anthony Johnson, Empire Genomics, LLC, Buffalo, NY

" We are sorry to learn about the financial troubles of the Atlas. It is a great resource and the community needs this. We would like to help you and the community out and have a few ideas."

  • Christopher Williams, PerkinElmer Inc., Cambridge, MA

" I have read with interest and concern the emails in the US about the possible closing of the Atlas of Genetics in Cancer. The value of this web site is quite evident through the volume of emails I have seen from clinicians asking others to support it. I would be happy to talk about the possible ways we could contribute."

  • Suzanne Gollin, Otolaryngology and Pathology University of Pittsburgh Graduate School of Public Health and School of Medicine University of Pittsburgh Cancer Institute

"It is an incredibly useful resource."

  • Anwar Iqbal, President, Cancer Cytogenomics Microarray Consortium

" As you know we all use the atlas for providing the best patient care for cancer patients. I would greatly appreciate if (...) provide any assistance in preserving this important diagnostic tool. I will start brainstorming to explore possibilities for this important atlas which is used by the cancer cytogenetics community every day/night."

  • Hutton Kearney, President, American Cytogenetics Conference, Fullerton Genetics Center, Asheville, NC

" It is frightening for us all to hear that the Atlas might “die”, as it is an invaluable resource for our community."

  • Terry B. Van Fleet, MDACC

"As a supervisor in the MD Anderson clinical cytogenetic labs I use the journal when I write reports for our cytogeneticsts to review and sign. I would like to become a member."

  • Fléchère Fortin, Montreal Children's Hospital McGill University Health Center

" Au sein de notre laboratoire, l'Atlas est un outil indispensable et il est impensable de ne plus y avoir accès. C'est pourquoi chacun des membres de l'équipe a effectué (ou effectuera sous peu) un don personnel. Par ailleurs, nous somme en train d'organiser un don institutionnel."

  • Suzanne Demczuk, Genetics Laboratory, Ellis Hall Royal University Hospital, Saskatoon SK, Canada

" Certainement, j’aimerais bien devenir membre de l'ARMGHM, mais surtout soutenir l’Atlas, qui est un outil que j’utilise très souvent dans la rédaction de mes résultats d’analyses cytogénétiques."

  • Kate Williamson, Publisher, Elsevier, Philadelphia, PA

" The Atlas by all accounts I’ve heard is an invaluable resource for the cytogenetics community."

  • Christine R. Bryke, Quest Diagnostics Nichols Institute, Chantilly, VA, USA

" At Quest Diagnostics we refer to the Atlas on a daily basis when signing out bone marrow chromosome analyses. We do not want to lose this valuable resource."

  • On behalf of the WHGD, Marian Stevens-Kroef, Universitair Medisch Centrum, Nijmegen, The Netherlands

" We certainly see the importance of the Atlas of Genetics and Cytogenetics in the field of tumorcytogenetics, and hope that this website remains available in the future."

  • Ian Brooks, Cytogenetics Department, VCGG, Royal Children’s Hospital Melbourne Australia

" I work at the Royal Children’s Hospital Melbourne Australia as part of a small team of oncology cytogeneticists. I was happy to make a donation as I use the Atlas regularly and your service would be greatly missed if it were to close due to lack of money."

  • Nyla A. Heerema, Department of Pathology, The Ohio State University, Columbus, OH, USA

" I am happy to be of help. The Atlas is invaluable."

  • Jürgen Kunz, Laborleitung Zytogenetik, IMMD Institut für Medizinische Molekular Diagnostik GmbH, Berlin, Germany

" We, the BVDH, want to support your project, because the Atlas is an extreme useful tool for our members which are working in the field of tumorcytogenetics."

  • Raheel Nawaz, National Centre for Text Mining (NaCTeM), University of Manchester, UK

" My colleagues and I have recently stumbled on the Atlas Oncology website/database. We believe that it is a very useful resource for locating oncogene mentions in research articles."

  • Jen-Chieh Lee, National Taiwan University Hospital, Taipei, Taiwan

"... First of all, I have to say your website is really a nicely organized treasury of knowledge..."

  • Anonymous

"It is very useful with pictures from cytogenetic aberrations, particularly on rare abnormalities. I believe you encourage collaborations, but I don´t really know, how to proceed. Perhaps having a list of chromosomal locations that you would like more pictures from would help..."

"The website gives a good overview of cytogenetic rearrangements in leukemia and lymphoma. It is however essential also to check Mitelman Database when you want to check for rare or not-listed translocations/rearrangements."

"Please continue the Atlas and update on a regular basis. It is a valuable resource not only to the Cytogenetics Laboratory (both technologists and directors) but for Pathology/Hematopathology resident education and medical genetics fellowship education".

"What would we do without this incredible resource?!?!?!? You are so special to all of us in the cytogenetics field - from lab technologist to laboratory director. THANK YOU!!!!"
"Excellent resource"

"LOVE YOUR WEBISTE, REALLY HELPS US WITH ALL OUR PATIENTS. THANK YOU :)"

"Good source of relatively up-to-date information. It is useful to be able to access the data from different directions i.e. view by chromosome rearrangement, by genes on that chromosome or by leukamia type. A very useful research tool. Many thanks"

"The example of chromosome images for the translocations posted are very helpful."

"Very useful resource for things I only come across occasionally. Thank you."

"The Atlas is a very valuable resource, used often to assist with reporting cancer cytogenetics cases. Thank you for maintaining this excellent database."

"The Atlas is an invaluable tool for a director of a clinical cytogenetics laboratory. I understand it is a huge task, but I wish the references were a little more current."

"I rely a great deal on this web site. Please keep up the wonderful work!"

"Excellent resource. I have used it for reporting results on my patients, teaching my students and for learning as a student."

"Invaluable resource and great starting point for any literature search on relevant topics. Some pages understandably become out of date which is why I use the atlas as a starting point rather than definitive refererence".

"I am a cytogenetic technologist who uses the atlas every day. In our hospital-based clinical cytogenetics lab, the technologists who work on neoplastic specimens write reports, and we rely very heavily on the Atlas to do our job. We find the Atlas to be the most accessibly organized resource available to us on the Web, and we really appreciate the work that has gone into making this available to us! Thank you, and we hope that the Atlas continues to be updated, and made available to the general public!"

"Found the atlas by chance and am impressed, it is very useful, thank you!"

"Keep up the good work."

"I greatly appreciate the atlas and utilize it often to aid in my intepretation of abnormal cases. It is also a wonderful educational resource. Thank you very much for maintaining it!!"

"Well organized and extremely helpful material."

"The images (banding and FISH) are extremely helpful in interpreting cytogenetic aberrations in the routine lab. And so is the accompanying molecular and clinical information. It's a great website!"

  • Donations with comments

"To keep Atlas open Cytogenetics Cleveland loves it!!" Miranda Dornis.

"To join the association to keep Atlas of Genetics and Oncology alive." Hana Aviv.

"To maintain this site, this site contributes a lot to Geneticists around the World." Aswani Yenamandra.

"Contribution to this great resourse." Loris McGavran.

"To keep the Atlas on going " Mary Kochera

"Donate for Atlas." MLL Münchner Leukämielabor GmbH

"Support website" Soo Cheong

"Donation to keep the Atlas" Angelica Hernandez-Jardines

"Help Atlas survive" Michele Kempik

"Donation to the Atlas" Nagesh Rao

"Support for Atlas" Berna Beverloo

 

A bug, on May the 23rd, 2008...

A bug, on May the 23rd, 2008, was devastating: pages on chromosomes, with their data, had vanished; many mails were sent to us, proving that the Atlas was (is) indispensable.
Some of these mails are herein below:


De : Stephenson, Christine [mailto:----
Envoyé : samedi 24 mai 2008 00:46
Objet : new version of atlas
Dear Jean-Loup Huret

Re: Atlas of Genetics and Cytogenetics in Oncology and Haematology

I was on the Atlas site today and reviewed the new format. I am very appreciative of all the additional information that has been added. It will be of much benefit to many people. However, I do have some feedback that I thought you might appreciate and be able to pass on regarding the web design and layout.

My staff uses this site frequently to find and reference information on cytogenetic changes in hematological disorders and found the previous format of clicking on a chromosome number and that bringing up a list of all the translocations and rearrangements associated with that chromosome very helpful. Now the only way to do this is to go to a specific disorder and see if that chromosome is involved. This is more time consuming and not as user friendly. Since I have had a stream of people come to my office today to comment on this I thought I would pass on the comments in order to be helpful not critical.

Thank you for your consideration of these comments and my thanks for the information that this site provides. It is an invaluable tool and a great contribution to the genetics community.

Sincerely,

Christine F. Stephenson, Ph.D., FACMG
Laboratory Director, Cytogenetics
Genzyme Genetics, Phoenix, AZ.



De : Barbara Dupont [mailto:----
Envoyé : vendredi 23 mai 2008 23:30
Objet : chromosome aberrations
Where are the chromosome aberrations listed in the current version of the atlas? Where is all of the information on translocations etc?/ Genes are fine but …
Help! I loved this site when I was writing difficult bone marrow reports.
Barbara R DuPont, PhD, FACMG
Cytogenetics Laboratory Director
Greenwood Genetic Center
125 Gregor Mendel Circle
Greenwood, SC 29646



De : Meck, Jeanne M [mailto:----
Envoyé : vendredi 23 mai 2008 20:39
Objet : Atlas of Genetics and Oncolocy
Dear Dr. Heuret,
My colleagues and I are avid users of your extraordinary website. It is the single most important tool for cytogeneticists and I have been educating pathologists to use it as well. We noticed today that when you click on a chromosome number, that you don't get the seletion of abnormalties associated with that chromosome. Is this a temporary change? Hopefully, it is because it makes clinical correlations very much more difficult.

Again, thank you very much for this very valuable website!
Jeanne
Jeanne M.Meck, PhD
Technical Director, Cytogenetics Laboratory
Quest Diagnostics / Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20151

Quest Diagnostics
Nichols Institute
www.nicholsinstitute.com
mobile.nicholsinstitute.com for Smart Phones



De : Eric B.Johnson [<mailto:----
Envoyé : vendredi 23 mai 2008 20:01
Objet : Website problems?
Are there problems with the Atlas website? It seems the abnormality descriptions are missing. Only the losses/amplicon section has anything in it (nothing in the leukemia, solid tumor, cancer prone diseases).
Eric J.
<><><><><><><><><><><>
Eric B. Johnson
UW Cytogenetic Services
465 Henry Mall, Room 419
Madison, WI 53706



De : Dal Cin, Paola,Ph.D. [mailto:----
Envoyé : vendredi 23 mai 2008 19:10
À : HURET J L
Objet : Web side, and more
Dear dr Huret, I saw a new look for entity by chromosome in the web. . For example, clicking on chromosome 20, now there is a Leukemia and Solid Tumor folder , but click on it nothing happen. To get all aberrations reported I need to go in the entity by Theme, and after leukemia, and look for each entity. Is this normal?
Moreover, I hope to send to you the Endometrial Stromal Sarcoma review, there is something new and I want to incorporate this findings so it is truly up-date, best wishes, Paola
Paola Dal Cin, Ph.D.
Cytogenetics Laboratory
Department of Pathology
Brigham and Women's Hospital
75 Francis Street, Amory 3-154
Boston, Massachusetts 02115



De : Cowan, Janet [mailto:----
Envoyé : vendredi 23 mai 2008 18:08
Objet : Changes in web site
Hi!
I went to the web site to check on rearrangements involving 2p and 22q. I couldn't find a link to any of the lovely pictures you have of recurrent translocations - have they moved? Even for chromosome 9 there is just the ideogram and titles to the right for leukaemia, solid tumors and cancer prone diseases.
Thanks!
Janet
Janet M. Cowan, Ph.D., FACMG
Director Cytogenetics, Tufts Medical Center
Director ABMG Training Program
Associate Professor Pediatrics, TUSM
800 Washington Street, Box 188
Boston, MA 02111



De : Meloni-Ehrig, Aurelia M [mailto:----
Envoyé : vendredi 23 mai 2008 16:31
Objet : atlas web site issue
Hi,
I am a frequent user of the Atlas of chromosomes in cancer web site (<http://atlasgeneticsoncology.org/Indexbychrom>http://atlasgeneticsoncology.org/Indexbychrom). Today, when I accessed the web site, I noted that the format is changed to the point that is not longer user friendly. When I select a chromosome number, for example chromosome 2, there is no longer a list of chromosome abnormalities relative to that chromosome. I am wondering if this is a temporary problem or if we no longer have access to the list of chromosomes abnormalities as we did previously.

I look forward to your reply.
Sincerely,
Aurelia Meloni-Ehrig, Ph.D., D.Sc., ABMG
Scientific Director
Cytogenetics/Oncologyf?
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20151

Donate now

  • by credit card, on our platform for secure online payment using PayPal :

Donate (in Euros)

Donate (in US Dollars)

 

 


 

SCIENTIFIC SOCIETIES SUPPORTS

European Cytogeneticists Association

"Your letter was discussed at the last ECA executive board session. We decided to support your database which is very helpful for medical geneticists."

Lettre de soutien de l'ECA 2011

Groupe Francophone de Cytogénétique Hématologique (French Cytogenetics Society)

"Le bureau du GFCH a émis un avis très favorable pour que le dossier du Dr Jean-Loup Huret concernant l’Atlas soit soutenu.En effet, ce site international, créé par un des membres du GFCH, est d’une grande utilité pour les médecins travaillant dans le champ de la génétique des hémopathies malignes."

Société Française du Cancer

"Cet atlas a particulièrement intéressé la Société Française du Cancer car il est à la convergence de l’enseignement post-universitaire interactif, de la recherche, et bien entendu du soin cancérologique. (...)
Cette banque de données sur la cytogénétique des cancers arrive à un moment particulièrement opportun où l’on sait que plusieurs centaines de gènes sont impliqués dans le cancer et que l’on est à la veille de la naissance d’une nouvelle classification des cancers de l’organisme à travers cet outil.
C’est donc sans réserve que la Société Française du Cancer a décidé de soutenir cette encyclopédie (...)
Le remarquable travail réalisé par J.-L. Huret pour le mantien de ce site mérite d’être non seulement pérennisé mais encore développé (en mobilisant de nouvelles énergies humaines et en apportant les financements essentiels, non seulement à son maintien mais à son développement).
La S.F.C pour sa part encouragera ses membres à se mobiliser pour ce projet."

Société Française de Génétique Humaine (SFGH) et Société Française de Génétique (SFG)

" … la Société Français de Génétique (SFG) et la Société Française de Génétique Humaine (SFGH) souhaitent témoigner leurs soutiens à l’action de M. J-L. Huret dans le maintien du site web http://www.infobiogen.fr/services/chromcancer/ .
Ce site intitulé " Atlas of Genetics and Cytogenetics in Oncology and Hematology " est de grande qualité, apprécié à la fois des médecins, des biologistes et des chercheurs dans les domaines de la cancérologie et de l’hématologie. Un travail colossal a été effectué par Mr Huret, et la survie de cet outil de travail précieux à de nombreux professionnels français et européens dépend exclusivement de lui actuellement. Un effort constant est nécessaire pour intégrer les nouvelles informations dans ces domaines et actualiser régulièrement les documents déjà mis en ligne. Ceci ne pourra se faire sans aides financières et humaines, que nos deux Sociétés Savantes appellent sans réserves de leurs vœux."

Lettre de soutien de la SFGH 2011

Société Française d’Hématologie

" Au nom de l’ensemble des membres de la Société Française d’Hématolot?gie, je souhaite apporter tout le soutien nécessaire de notre société savante à l’action du Dr Huret menée pour le maintien et le développement du site intitulé " Atlas of Genetics and Cytogenetics in Oncology and Hematology ". Il s’agit d’un travail remarquable contenant des informations de grande valeur.
(...) un soutien financier pérenne de ce site doit être mis en place … "

Institut National du Cancer

" … Permettez-moi d’abord de vous féliciter du travail que vous avez réalisé, et dont j’ai pu constater la qualité en me rendant sur le site (...) en vous félicitant encore de ce que vous avez fait et en espérant que vous trouverez les moyens de votre développement. "

Association des Cytogénéticiens de Langue Française (ACLF)

"...Ce site est utilisé de façon régulière par les cytogénéticiens qui s'y réfèrent pour leur pratique quotidienne. Dans un domaine scientifique et médical où les connaissances évoluent très rapidement, l'information est à la base d'une analyse et d'une interprétation génétique de qualité, et la disparition d'un tel site (ou de son libre accès) ne serait pas sans conséquence sur l'activité des laboratoires..."

Lettre de soutien de l'ACLF 2011

Lettre de soutien financier de l'ACLF 2011

 

Donate now

  • by credit card, on our platform for secure online payment using PayPal :

Donate (in Euros)

Donate (in US Dollars)

 

 


 

The ATLAS in SCIENCE and NATURE

Nature Reviews Cancer
Science Magazine
Nature

 

Nature Reviews Cancer

Can a single web site catalogue all the genetic changes in every type of cancer? This is the ambitious aim of the Atlas of Genetics and Cytogenetics in Oncology and Haematology, although its editor, Jean-Loup Huret (University Hospital, Poitiers, France), admits that the task will never be complete. The peer-reviewed atlas allows users to search through several different headings. The genes section contains concise summaries of oncogenes and tumour suppressors. Each gene has a 'card' listing its salient features, cancers in which the gene is implicated and links to other sources of information. The choice of entries belies a bias towards haematological malignancies, however, and there are some striking oversights (INK4A, ARF and MDM2 are missing, for example).

The 'leukaemias' section shuffles the cards according to chromosomal rearrangement. Here, you'll find notes on clinical features, treatment, other cytogenetic abnormalities that cluster with the rearrangement in question, the genes involved and references. There's a similar section for solid tumours, this time organized according to tumour type. Other sections include a deck of cards on cancer-prone disorders, 'deep insight' articles, which go into more detail than is possible for the standard database entries and links to related resources.

The database provides an enormous amount of information in a user-friendly format, but perhaps it would be more successful if it was less ambitious. For the cytogeneticist, it provides a useful adjunct to the Mitelman Database of Chromosome Aberrations in Cancer. The Atlas also welcomes contributions, so if your favourite gene or translocation is missing, why not let the curators know?

Cath Brooksbank
Nature Reviews Cancer 1, 179 (2001); doi:10.1038/35106056
WEB WATCH Chopping and changing

 

Science Magazine

Much about cancer remains a mystery, but one thing is clear: Many tumors bear specific genetic signatures, changes that apparently make cell division run amok. A wealth of information on these mutations can be found at the Atlas of Genetics and Cytogenetics in Oncology and Haematology, a peer-reviewed site in France aimed at both researchers and clinicians. For each of 260 or so major genes known to be involved in cancer, visitors will find a "card" — an up-to-date summary — that describes the mutations, the altered protein that gene makes, and the type of tumor in which it's found. Links lead to more information in protein, gene, and MEDLINE databases. Other cards describe types of solid tumors and leukemias, as well as inherited diseases, such as piebaldism, that raise cancer risk.

The site's curators are also compiling several other useful resources: cancer genetics links, review papers, and teaching materials, including a primer on chromosomal abnormalities. In the site's first 4 years, 150 researchers have contributed; all the same, "we need more authors," e-mails editor Jean-Loup Huret of Poitiers University.
www.infobiogen.fr/services/chromcancer

NetWatch
Volume 292, Number 5523, Issue of 08 June 2001 ©2005 by The American Association for the Advancement of Science.

 

Nature

Lifelines: Browsing the cancer catalogue

Researchers need maps to the vast territory of cancer genetics. © Atlas of Genetics and Cytogenetics in Oncology and Haematology The field of cancer is vast, that of genetics gigantic. Combine the two and researchers risk data overload. So online resources and databases that collate and sift information on cancer genetics are proving invaluable. Now a site that features broken chromosomes joins the fray1. Hundreds of genes are already implicated in causing cancer, which arises when normally placid cells start to multiply uncontrollably. With the sequencing of the human and mouse genomes, data on cancer-linked genes is set to rocket. "I thought that knowledge was increasing too much," says Jean Huret of University Hospital in Poitiers, France, "and someone needed to write it down."

Researchers need maps to the vast territory of cancer genetics.
© Atlas of Genetics and Cytogenetics in Oncology and Haematology

With contributors across Europe and the United States, Huret is collating the ever-expanding body of information on cancer-implicated genes into the Atlas of Genetics and Cytogenetics in Oncology and Haematology. "It's a huge task," he says. The database, which is divided into 'cards' or reviews of genes and tumour types, is aimed at cancer specialists — doctors and researchers. "It will never be complete," says the man who has a 'Work in Progress' road sign on his site. "It can be daunting," agrees James Metz of the University of Pennsylvania Medical Center and editor-in-chief of Oncolink, one of the largest and oldest cancer-information websites. Containing over 70,000 online documents, Oncolink is used by patients and professionals. Says Metz: "There is a need for more and more information." Rearrangements of chromosomes — coiled up packets of DNA — are frequently associated with cancers, and are included in Huret's and others' databases. One hotspot on the eleventh of our 23 chromosomes has at least 54 reported rearrangements — all associated with the blood cancer leukaemia. And in some cancers, the type of rearrangement can affect their diagnosis and response to treatment.

Chromosome rearrangements are often implicated in cancer.
© Atlas of Genetics and Cytogenetics in Oncology and Haematology

"The goal is to target therapy to these specific changes," explains Ilan Kirsch, who leads part of the US National Cancer Institute's Cancer Genome Anatomy Project (CGAP). This would be preferable to the current approach of blitzing tumours with radio- or chemotherapy.
CGAP ambitiously aims to define fully the genetics that underpin different cancers, and hosts a cancer-information website for researchers. "[Databases] are the name of the game for the next few years," says Kirsch.

1. Huret, J. L. An atlas on chromosomes in hematological maliganancies. Example: 11q23 and MLL partners. Leukemia 15, 987 999 (2001).

 

Helen Pearson
© Macmillan Publishers Ltd 2001 Reg. No. 785998 England

 

Donate now

  • by credit card, on our platform for secure online payment using PayPal :

Donate (in Euros)

Donate (in US Dollars)

 

 


 

NOMINATED for an AWARD